Cargando…
Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
BACKGROUND: Activated immune cells (IC) in the tumor microenvironment (TME) are critical for anti-tumor efficacy. Greater understanding of the dynamic diversity and crosstalk between IC is needed to clarify their association with immune checkpoint inhibitor efficacy. METHODS: Patients from three tis...
Autores principales: | Ye, Dingwei, Desai, Jayesh, Shi, Jingwen, Liu, Si-Yang Maggie, Shen, Wei, Liu, Tengfei, Shi, Yang, Wang, Dan, Liang, Liang, Yang, Silu, Ma, Xiaopeng, Jin, Wei, Zhang, Pei, Huang, Ruiqi, Shen, Zhirong, Zhang, Yun, Wu, Yi-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990338/ https://www.ncbi.nlm.nih.gov/pubmed/36879284 http://dx.doi.org/10.1186/s40364-023-00465-w |
Ejemplares similares
-
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
por: Lu, Zhihao, et al.
Publicado: (2022) -
Evaluation of the EdgeSeq Precision Immuno-Oncology Panel for Gene Expression Profiling From Clinical Formalin-Fixed Paraffin-Embedded Tumor Specimens
por: Shi, Yang, et al.
Publicado: (2022) -
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
por: Shen, Lin, et al.
Publicado: (2020) -
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
por: Desai, Jayesh, et al.
Publicado: (2023) -
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
por: Song, Yuqin, et al.
Publicado: (2022)